Comparison of CD38, ZAP70 and hTERT expression with known prognostic markers in patients with chronic lymphocytic leukemia during five-year follow- up period [Kronik lenfositik lösemili hastalarda bilinen prognostik belirteçlerin cd38 zap70 ve htert ekspresyonları ile beş yıllık takip döneminde karşılaştırılması]

Basit Öğe Kaydı
dc.contributor.authorVural F.
dc.contributor.authorKaraca E.
dc.contributor.authorSoyer N.
dc.contributor.authorGunduz C.
dc.contributor.authorSahin F.
dc.contributor.authorKosova B.
dc.contributor.authorSaydam, G..
dc.contributor.authorCagirgan S.
dc.contributor.authorTombuloglu M.
dc.contributor.authorÖzkınay F.
dc.contributor.authorCogulu O.
dc.date.accessioned2019-10-27T08:22:10Z
dc.date.available2019-10-27T08:22:10Z
dc.date.issued2014
dc.departmentEge Üniversitesien_US
dc.description.abstractChronic Lymphocytic Leukemia (CLL) is the most common leukemia in adults. Recently CD38, ZAP70 and hTERT activity have been studied for the evaluation of the prognosis of CLL besides clinical staging and lymphocyte doubling time. There are inconsistent results regarding these markers for the evaluation of the prognosis in CLL patients. In this study CD38, ZAP70 and hTERT values in CLL patients were measured to make comparisons between each other and known prognostic factors. Thirty CLL patients who were included in the study were followed up for 5 years after the initial diagnosis. The mean hTERT value in CLL and control cases were 1.00±1.31 and 3.89±3.58, respectively (p< 0.05). The mean CD38 and ZAP70 were 6.20±7.60 and 5.51±5.67, respectively. No significant association was detected between CD38, ZAP70 and hTERT activity. There was no correlation between those parameters and known prognostic parameters such as Rai staging, peripheral lymphocyte levels, age, and sex of the patients, beta-2 microglobulin and reply to treatment in CLL. The overall five-year survival rate in CLL patients is 96.7%. The overall five-year survival rate in CLL patients is 96.7%. In conclusion, further studies including larger series of patients with longer follow-up periods are recommended. © 2014, UHOD - Uluslararasi Hematoloji Onkoloji Dergisi. All rights reserved.en_US
dc.identifier.doi10.4999/uhod.14557
dc.identifier.endpage184en_US
dc.identifier.issn1306133X
dc.identifier.issn1306-133Xen_US
dc.identifier.issue3en_US
dc.identifier.scopusqualityQ4en_US
dc.identifier.startpage179en_US
dc.identifier.urihttps://doi.org/10.4999/uhod.14557
dc.identifier.urihttps://hdl.handle.net/11454/26195
dc.identifier.volume24en_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherUHOD - Uluslararasi Hematoloji Onkoloji Dergisien_US
dc.relation.ispartofUHOD - Uluslararasi Hematoloji-Onkoloji Dergisien_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectCD38en_US
dc.subjectChronic Lymphocytic Leukemiaen_US
dc.subjectHTERTen_US
dc.subjectZAP70en_US
dc.titleComparison of CD38, ZAP70 and hTERT expression with known prognostic markers in patients with chronic lymphocytic leukemia during five-year follow- up period [Kronik lenfositik lösemili hastalarda bilinen prognostik belirteçlerin cd38 zap70 ve htert ekspresyonları ile beş yıllık takip döneminde karşılaştırılması]en_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu